Prantae Solutions raises Rs 5 crore in seed round from IAN Group

New Delhi: Prantae Solutions, a pioneering deep-tech company specializing in next-generation diagnostic innovations, has raised Rs 5 crores in a seed funding round led by the IAN Group, with participation from investors IAN Alpha Fund, Samir Kalia, Deepank Kumar, and Nitin Zamre.

With a mission to transform healthcare into a realm of inclusivity and empowerment, Prantae is redefining diagnostics by developing cutting-edge point-of-care solutions to address chronic health conditions like chronic kidney disease (CKD) and preeclampsia.

The funding will support the launch of complementary diagnostic solutions for kidney health and diabetes care, further enhancing Prantae’s product portfolio. Investments in research and development will continue to drive innovation, ensuring the company remains at the forefront of deep-tech diagnostics.

Headquartered in Bhubaneswar, Odisha, the company leverages its strong intellectual property to deliver accurate, timely, and actionable diagnostic tools. Their flagship product, Proflo-U®, revolutionizes kidney health assessment with its globally unmatched detection range for microalbumin to proteinuria levels. Powered by proprietary nanosensors, IoT, and AI technology, Proflo-U® offers calibration-free, cost-effective, and user-friendly testing solutions designed to improve patient outcomes and reduce healthcare costs.

Sumona Karjee Mishra, Chairman & Managing Director, Prantae Solutions, said, “With the invaluable support of Indian Angel Network, we are empowered to accelerate our journey toward transforming healthcare. This investment fuels our vision to deliver world-class point-of-care diagnostics with our flagship product Proflo-U, and champion early detection and personalized kidney care. Together, we are creating a future where innovation meets compassion, redefining health outcomes for communities everywhere.”

Padmaja Ruparel, Co-founder, IAN Group, said, “Prantae Solutions is a stellar example of how deep-tech innovations can address critical healthcare challenges, especially in underserved markets. Their transformative diagnostic tools have the potential to make healthcare more inclusive and accessible, not just in India but globally. We are proud to back a team that combines exceptional innovation with a deeply personal mission to create meaningful impact.”

The founders of Prantae, Aseem and Sumona, share a journey rooted in passion and resilience. Having first met as PhD batchmates in 2004, their shared dedication to deep-tech and biotechnology led them to represent India in the Biotech Entrepreneurship Challenge (2007-2008) in London. A pivotal moment in their lives occurred during Sumona’s pregnancy in 2010 when a lack of early diagnostic tools for preeclampsia resulted in a life-threatening situation. This personal ordeal motivated them to launch Prantae Solutions in 2015 to bridge critical diagnostic gaps and improve healthcare accessibility.

CKD is a global health crisis affecting over 700 million people, with a disproportionate burden in low- and middle-income countries like India. Timely diagnosis and early intervention are crucial for slowing CKD progression and improving patients’ quality of life. Prantae’s innovative solutions aim to address these challenges, particularly through Proflo-U®, a palm-top diagnostic device that ensures rapid and precise assessments.

The point-of-care (POC) diagnostics market in India, valued at USD 1.41 billion in FY2024, is projected to grow at a CAGR of 8.47%, reaching USD 2.71 billion by FY2032. Globally, the market is expected to grow from USD 30.87 billion in 2023 to USD 51.19 billion by 2032. The company’s innovative products are poised to capitalize on this growing demand for accessible and cost-effective diagnostics.

Prantae aims to establish a strong domestic presence before expanding to international markets. With its commitment to building highly differentiated point-of-care products, the company is set to transform healthcare diagnostics and improve accessibility for millions worldwide.